

May 14, 2021

To: All Concerned Parties

Company Name: Solasia Pharma K.K.  
Representative: Yoshihiro Arai, President & CEO  
(Code number: 4597, TSE Mothers Section)  
Contact: Toshio Miyashita, CFO, Director  
Tel: 81-3-5843-8049  
URL: <https://solasia.co.jp/en/>

## **Solasia Announces Completion of Exercise of Series 11 Warrants**

Tokyo, Japan, May 14, 2021 – Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), today announced completion of exercise of all of Series 11 warrants. The summary is as follows.

1. Series 11 Warrants Issue and Allocation Date: August 31, 2020
2. Series 11 Number of Warrants: 140,000
3. Series 11 Warrants Underlying Shares: 14,000,000 shares
4. Series 11 Warrants Allottee: Macquarie Bank Limited
5. Redemption of all Unsecured straight bonds issued at the same time on August 31, 2020 was completed in March 2021, and Series 12 Warrants issued at the same time on August 31, 2020 has not been exercised.

###